In patients with melanoma, PTEN deletion in tumor cells increases the expression of immunosuppressive cytokines and reduces the infiltration of T cells, which likely accounts for the dismal outcomes of Anti-PD-1 therapy (Trujillo et al., 2019). This evidence concerns the gene PTEN and melanoma.